In the last three years, a new technique for reprogramming adult cells has given scientists an easier and less controversial way to harness the power of embryonic-like stem cells to study human disease from its earliest beginnings in hopes of gleaning new insights into the root causes of disease and developing new therapies...
Osiris Therapeutics, Inc. (NASDAQ:OSIR) announced that it is resuming enrollment in its clinical trial evaluating Prochymal for patients with treatment-resistant Crohn's disease...
NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer® technology, announced the successful completion of the first-in-human clinical trial with Spiegelmer® NOX-A12...
UCLA AIDS Institute researchers successfully removed CCR5 - a cell receptor to which HIV-1 binds for infection but which the human body does not need - from human cells. Individuals who naturally lack the CCR5 receptor have been found to be essentially resistant to HIV...
Working with mice, Johns Hopkins scientists who tested drugs intended to halt growth of brain cancer stem cells a small population of cells within tumors that perpetuate cancer growth conclude that blocking these cells may be somewhat effective, but more than one targeted drug attack may be needed to get the job done...